Navigation Links
Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study

stablishing appropriate doses for our later-stage clinical study, and I am pleased to say we accomplished both,” said Dr. Suhail Nurbhai, MRCP, Vice President of Clinical Development at Dynogen. “DDP733, which targets the GI motility abnormalities central to GERD, has demonstrated a statistically significant reduction in the number of reflux events at a dose of 0.5 mg in this trial. We are now planning a larger Phase 2 study in GERD patients, where we will further build on these very promising results.”

In February of this year, Dynogen announced positive results from its Phase 2 study of DDP733 in IBS-c, with a statistically significant improvement over placebo in the Subject Global Assessment of IBS. The Company plans to initiate a Phase 2b study in IBS-c this year.

About DDP733

DDP733 is an oral, partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. Preclinical studies of DDP733 established the compound’s prokinetic properties (the ability to promote the motility of the GI tract). Dynogen’s preclinical studies have also shown that DDP733 is minimally absorbed by the cells lining the gastrointestinal tract and, as a result, more of the product candidate remains available at the desired local site of action. A recently completed Phase 2 study of the candidate as a treatment for IBS-c demonstrated an overall clinical response rate of 54% in patients receiving a dose of 1.4 mg t.i.d. compared to a 15% clinical response rate for patients receiving placebo, and the drug was also well-tolerated. Previous clinical studies of the compound have demonstrated favorable safety and pharmacokinetic profiles. Dynogen has exclusive rights under issued U.S. and European patents related to the use of DDP733 as a treatment for GERD.

About Nocturnal Gastroesophageal Reflux Dis
'"/>




Page: 1 2 3

Related medicine technology :

1. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
2. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
3. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
4. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
5. Interferon Beta DNA Treatment Delivered with Ichor Technology Reduces Atherosclerosis Progression in Mice
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dynogen DDP733 Reduces Reflux Phase GERD Study
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... an intimidating job description: ensure products meet quality standards ... tight budgets and escalating regulations, quality leaders also have ... costs and risk. Those who don,t effectively ... quality function as well as marketplace failure and regulatory ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
(Date:3/27/2015)... WASHINGTON , March 27, 2015 ... - The biopharmaceutical industry comes out on top as ... in a new report  from ndp│analytics. According to ... and development (R&D) investment over the last decade, accounting ... 2000-2012. A Short Video on ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Week in Review: The Latest from PhRMA 2
... 17 Regado Biosciences, a privately held company leading the ... David J. Mazzo , PhD, President and CEO, will be presenting ... in Boston, Massachusetts . Dr. Mazzo,s presentation will be given ... in the Robinson Room and will include an overview of ...
... June 17 Salvin Dental Specialties, Inc. and LifeNet Health ... advance LifeNet Health,s OraGraft™ allograft products in the dental market. , ... The two companies ... the existing relationship between these two companies, which provides LifeNet Health ...
Cached Medicine Technology:Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 2Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 3LifeNet Health and Salvin Dental Specialties Announce Partnership 2LifeNet Health and Salvin Dental Specialties Announce Partnership 3
(Date:3/29/2015)... (PRWEB) March 29, 2015 Youth Villages ... counties in Oregon to assess the feasibility of implementing ... emotional and behavioral problems and their families. , Third ... select participants that will be provided technical assistance throughout ... counties join six other national awardees chosen by Third ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... W. Brickner, “and as we learn more about the ... , In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... homeostatic health, or endo-healing, is celebrated. Publius, of The ... four 2015 National Institutes of Health (PubMed) cannabinoid system ...
(Date:3/28/2015)... AZ. (PRWEB) March 28, 2015 Could ... to a new study by researchers at ... , Produced with the support of the Coffee and ... journal Molecular Psychiatry this past fall, the study—one of ... meta-analysis of genomic data from more than 120,000 regular ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
... memory in Alzheimer disease mice , Overactivation of ... formation, has been linked to Alzheimer disease. Ottavio Arancio ... shown that two different drugs that inhibit calpains can ... (APP/PS1 mice), leading them to suggest drugs that target ...
... Goals of All Parties -, MONETT, Mo., July ... ), a leading provider of integrated technology solutions,and data ... agency outsourcing solution has been bought by the,business line,s ... the,transaction were not disclosed., Banc Insurance Services, Inc. ...
... ABABA, Ethiopia, July 1 The U.S.,Agency for International ... the USA to combat HIV/AIDS in Ethiopia. The program ... vital medical,services and improve existing care and prevention programs ... and Adama. It will,also build community networks by means ...
... rise with temperatures , , TUESDAY, July 1 (HealthDay News) -- ... heat-related health issues because their bodies don,t cool down as ... not feel hot when the temperature is dangerously high and ... bodies have lost too much water," Dr. John B. Murphy, ...
... guide Foundation,s efforts, including polio,eradication, EVANSTON, Ill., July ... office on July 1 as chair of The,Rotary Foundation ... polio in its last remaining strongholds -- which include ... Foundation this year," said Majiyagbe.,"It is abundantly clear to ...
... SALT LAKE CITY, July 1 Dynatronics,Corporation (Nasdaq: ... a,letter from NASDAQ stating that for the last 30 ... has closed below the minimum $1.00 per,share requirement for ... company will be given 180 calendar days, or until ...
Cached Medicine News:Health News:JCI online early table of contents: July 1, 2008 2Health News:JCI online early table of contents: July 1, 2008 3Health News:JCI online early table of contents: July 1, 2008 4Health News:JCI online early table of contents: July 1, 2008 5Health News:JCI online early table of contents: July 1, 2008 6Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 2Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 3Health News:USAID Announces Youth-Focused HIV/AIDS Programs in Ethiopia 2Health News:Extreme Heat a Deadly Risk for Older Adults 2Health News:The Rotary Foundation's First African Trustee Chair Takes Office 2Health News:The Rotary Foundation's First African Trustee Chair Takes Office 3Health News:Dynatronics Receives NASDAQ Minimum Bid Price Deficiency Letter 2
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
Medicine Products: